SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is gaining traction as community members rally around the project's potential and positive outlook, particularly within the Solana ecosystem. Discussions highlight the coin's strong community, locked liquidity, and long-term vision. The 

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential for equity tokenization and real-world asset (RWA) integration, with JPM highlighted as a major financial firm utilizing the blockchain.  Community members are also weighing Solana against emerging infrastructure projects and meme coins on the network, expressing excitement for potential gains. The conversation also highlights the resilience of its ecosystem, specifically mentioning the WAGMI community.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending as a potential successor in the meme coin meta, drawing comparisons to $DOGE and $PEPE and generating excitement within its community. Discussions highlight its strong chart, potential for a breakout, and the narrative around its origins as part of a 'prophecy' alongside other successful meme coins. The community expresses strong conviction and anticipates significant growth, emphasizing its potential within the Ethereum ecosystem.

Pieverse

PIEVERSE is trending amid community discussion of potential short squeezes and liquidations, particularly in relation to Bitcoin's movements. Sentiment is further influenced by reports of scam concerns and observed trading bot activity, with some traders noting unusual volume and funding rate fluctuations.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending due to its strong, meme-driven community and constant engagement, with members actively promoting its unique 'infected' culture within the Solana ecosystem. The community emphasizes the fun, energetic vibes, and continuous meme creation, even during market dips. $PMV is positioning itself as a leading meme coin with a focus on community and cultural spread.

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Lantheus Holdings is trending due to a recent analyst upgrade from Truist Securities and positive sentiment around the company's potential acquisition targets, particularly Radiopharm Theranostics (RADX). Community discussions highlight LNTH's bullish momentum, potential for a buyout, and the company's strategic positioning in the radiopharmaceutical space with upcoming catalysts.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as the community discusses its high throughput and compliance-first architecture, positioning it as a potential infrastructure layer for global finance. Community members highlight its capabilities in handling transactions and its integration with a major fiat anchor. This makes Keeta an infrastructure play that complements existing ecosystems.

BlackRock Institutional Trust Company N.A. - iShares MSCI India ETF

iShares MSCI India ETF

The iShares MSCI India ETF ($INDA) is trending due to a mix of factors, including large investments from companies like Microsoft, AI developments, and trade-related discussions between the U.S. and India. Community members are weighing potential tariff impacts and analyzing technical indicators, while some suggest India may be a more attractive investment relative to China.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as the community discusses the potential impact of prediction markets and recent regulatory developments affecting competitors like Kalshi. Bullish sentiment is fueled by Missouri's sports betting launch, anticipation of the ESPN partnership, and overall positive outlooks for the sports betting sector. Some investors believe DraftKings is undervalued, expecting significant growth driven by upcoming sporting events and potential market share gains.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending due to discussions around rate cut expectations and potential impacts on small-cap companies, with some traders pointing to a rotation into small caps. Community members are actively debating potential breakout levels and whether the recent strength is sustainable, especially with upcoming economic data releases and Federal Reserve decisions on the horizon. There are also discussions around technical patterns and identifying key support and resistance levels for potential trades.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?

Mesoblast (NASDAQ:MESO) Shares Gap Up - Here's What Happened...

Mesoblast (NASDAQ:MESO) Stock Price Passes Below 50-Day Moving Average - Here's Why

Mesoblast (NASDAQ:MESO) Shares Pass Below 50-Day Moving Average - What's Next...

Mesoblast (NASDAQ:MESO) Shares Gap Up - Here's Why

Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next...

Mesoblast Appoints James M O'Brien New CFO

(RTTNews) - Mesoblast Ltd. (MESO, MSB.AX), an Australian regenerative medicine company, Monday announced the appointment of James M O'Brien as its US-based Chief Financial Officer or CFO. The company...

Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy

Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know 

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Mesoblast (MESO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorsmedia.mesoblast.com/static-files/45831458-f1fc-48e1-ae2c-ede16ee03af2">said</a> on Thursday it is awaiting the final minutes from the U.S. Food and Drug Administration (FDA) to provide timelines for potential filing for its late-stage product candidate Revascor. Nasdaq-listed shares of the company rose over 3% by Thursday morning.The biotechnology company is seeking to file an application for the approval of Revascor for the treatment of patients with ischemic chronic heart failure, characterized by an enlarged heart and insufficient blood flow to the organs and extremities of the body. The condition is estimated to affect 2% of the adult population of the United States.During the meeting held in the first week of June, there was general alignment on items regarding chemistry, manufacturing &amp; controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval, the company said.The firm added that it is now awaiting the final minutes from the FDA to determine the timeline for a potential approval filing.The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft versus host disease (SR-aGvHD). Ryoncil is currently approved for the treatment of pediatric patients two months of age and older, and the company is looking to expand the scope of its treatment to adults.On Stocktwits, retail sentiment around Mesoblast rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:634/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_10_45_51_AM_png_80e25b67b7.webp" alt="MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="634" height="63"><figcaption>MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the update from the company and said that it is at its “inflection point.”<stembedurl>https://stocktwits.com/Mani86/message/617651955</stembedurl><a href="https://stocktwits.com/symbol/MESO">MESO stock</a> is down by about 41% this year but up by nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cardinal-health-raises-fy25-earnings-guidance/chlgGvBRb6x">Cardinal Health’s Improved FY25 Earnings Guidance Draws Retail Cheer, Stock Inches Toward Record Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

Equity

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Current Price	$18.07
Prev Close	$18.40
Open	$18.44
Dividend Yield	0.00%
50-Day Moving Average	$16.84
Beta	1.38
Avg. Volume	190,486.84
PE Ratio	-21.36

52-Week High	$22.00
52-Week Low	$9.61
Market Capitalization	$2.32B
EPS (Annual)	-$0.8443
Price to Book	3.87
Revenue Per Employee	$211,960.04
Enterprise Value/EBITDA	N/A

MESO
Mesoblast limited.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MESO News

MESOMesoblast limited.